What is Neopharma?
Neopharma, founded in 2003 and headquartered in Abu Dhabi, United Arab Emirates, operates as a comprehensive pharmaceutical entity. The company's core activities encompass the development and provision of generic medicines, alongside robust contract manufacturing and dedicated research and development services. Its broad operational scope positions it as a key player in the regional healthcare supply chain.
How much funding has Neopharma raised?
Neopharma has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Neopharma?
The company's large-scale, late-stage funding context suggests a strategic pivot towards significant expansion or the scaling of its existing operations. This capital infusion is likely earmarked for enhancing manufacturing capabilities, broadening its generic drug portfolio, or accelerating its research and development pipeline. Neopharma's trajectory indicates a focus on solidifying its market position and potentially exploring new therapeutic areas or geographical markets.
See full Neopharma company page
